$19.25
1.48% yesterday
Nasdaq, Apr 03, 09:46 pm CET
ISIN
US0327241065
Symbol
ANAB
Sector
Industry

AnaptysBio, Inc. Target price 2025 - Analyst rating & recommendation

AnaptysBio, Inc. Classifications & Recommendation:

Buy
75%
Hold
25%

AnaptysBio, Inc. Price Target

Target Price $37.64
Price $19.29
Potential
Number of Estimates 11
11 Analysts have issued a price target AnaptysBio, Inc. 2026 . The average AnaptysBio, Inc. target price is $37.64. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 12 analysts: 9 Analysts recommend AnaptysBio, Inc. to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the AnaptysBio, Inc. stock has an average upside potential 2026 of . Most analysts recommend the AnaptysBio, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Revenue Million $ 91.28 48.51
431.93% 46.86%
EBITDA Margin -123.30% -238.44%
86.32% 93.38%
Net Margin -170.91% -325.76%
84.17% 90.60%

11 Analysts have issued a sales forecast AnaptysBio, Inc. 2025 . The average AnaptysBio, Inc. sales estimate is

$48.5m
Unlock
. This is
46.86% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$143m 56.17%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $91.3m 431.93%
2025
$48.5m 46.86%
Unlock
2026
$66.9m 37.89%
Unlock
2027
$82.8m 23.80%
Unlock
2028
$76.0m 8.20%
Unlock
2029
$135m 77.68%
Unlock

2 Analysts have issued an AnaptysBio, Inc. EBITDA forecast 2025. The average AnaptysBio, Inc. EBITDA estimate is

$-116m
Unlock
. This is
2.76% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-79.1m 29.69%
Unlock
, the lowest is
$-152m 35.22%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-113m 27.25%
2025
$-116m 2.76%
Unlock
2026
$-115m 0.65%
Unlock
2027
$-120m 4.58%
Unlock

EBITDA Margin

2024 -123.30% 86.32%
2025
-238.44% 93.38%
Unlock
2026
-171.81% 27.94%
Unlock
2027
-145.14% 15.52%
Unlock

11 AnaptysBio, Inc. Analysts have issued a net profit forecast 2025. The average AnaptysBio, Inc. net profit estimate is

$-158m
Unlock
. This is
0.27% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-89.7m 43.40%
Unlock
, the lowest is
$-203m 28.08%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-156m 15.79%
2025
$-158m 1.29%
Unlock
2026
$-151m 4.24%
Unlock
2027
$-169m 11.93%
Unlock
2028
$-195m 15.03%
Unlock
2029
$-146m 24.91%
Unlock

Net Margin

2024 -170.91% 84.17%
2025
-325.76% 90.60%
Unlock
2026
-226.24% 30.55%
Unlock
2027
-204.56% 9.58%
Unlock
2028
-256.33% 25.31%
Unlock
2029
-108.33% 57.74%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share $ -5.12 -5.19
15.79% 1.37%
P/E negative
EV/Sales 11.87

11 Analysts have issued a AnaptysBio, Inc. forecast for earnings per share. The average AnaptysBio, Inc. EPS is

$-5.19
Unlock
. This is
0.19% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-2.94 43.46%
Unlock
, the lowest is
$-6.66 28.08%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-5.12 15.79%
2025
$-5.19 1.37%
Unlock
2026
$-4.97 4.24%
Unlock
2027
$-5.56 11.87%
Unlock
2028
$-6.39 14.93%
Unlock
2029
$-4.80 24.88%
Unlock

P/E ratio

Current -3.71 0.00%
2025
-3.72 0.27%
Unlock
2026
-3.88 4.30%
Unlock
2027
-3.47 10.57%
Unlock
2028
-3.02 12.97%
Unlock
2029
-4.02 33.11%
Unlock

Based on analysts' sales estimates for 2025, the AnaptysBio, Inc. stock is valued at an EV/Sales of

11.87
Unlock
and an P/S ratio of
12.20
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 6.31 79.96%
2025
11.87 88.07%
Unlock
2026
8.61 27.48%
Unlock
2027
6.95 19.22%
Unlock
2028
7.57 8.94%
Unlock
2029
4.26 43.72%
Unlock

P/S ratio

Current 6.48 81.55%
2025
12.20 88.18%
Unlock
2026
8.84 27.48%
Unlock
2027
7.14 19.23%
Unlock
2028
7.78 8.94%
Unlock
2029
4.38 43.72%
Unlock

Current AnaptysBio, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
JP Morgan
Locked
Locked
Locked Mar 05 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 04 2025
Wells Fargo
Locked
Locked
Locked Feb 13 2025
Wedbush
Locked
Locked
Locked Feb 07 2025
HC Wainwright & Co.
Locked
Locked
Locked Feb 04 2025
Wolfe Research
Locked
Locked
Locked Feb 04 2025
JP Morgan
Locked
Locked
Locked Dec 19 2024
Analyst Rating Date
Locked
JP Morgan:
Locked
Locked
Mar 05 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 04 2025
Locked
Wells Fargo:
Locked
Locked
Feb 13 2025
Locked
Wedbush:
Locked
Locked
Feb 07 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Feb 04 2025
Locked
Wolfe Research:
Locked
Locked
Feb 04 2025
Locked
JP Morgan:
Locked
Locked
Dec 19 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today